Results 31 to 40 of about 5,403 (175)

Using Synthetic Glycans to Investigate Anti‐Glycan Antibodies and Explore Their Medical Potential

Angewandte Chemie International Edition, EarlyView.
Anti‐glycan antibodies are essential in health and disease. Access to novel glycan structures paves the way for progress in antibody profiling for biomarker discovery, antibody development, and vaccine design. We summarize the strategies to synthesize and utilize synthetic glycans for the development and application of anti‐glycan antibodies in basic ...
Fabienne Weber, Aina Valenti, Jiří Ledvinka, Oren Moscovitz, Peter H. Seeberger   +4 more
wiley   +1 more source

Efficacy, safety and cost‐effectiveness of CAR‐T therapy

British Journal of Clinical Pharmacology, EarlyView.
CAR T‐cells demonstrate high efficacy in blood cancers, including ALL, MM and DLBCL. Innovations target solid tumours despite challenges such as antigen escape. Combination therapies enhance the delivery and infiltration of CAR T cells. Toxicity, cost and resistance remain major barriers to clinical use.
Emina Karahmet Sher, Amina Džidić‐Krivić, Emma Pinjic, Nejra Selak, Kanita Omerbasic, Alexandar Chupin, Andrej Belancic, Almir Fajkic   +7 more
wiley   +1 more source

Radioimmunotherapy of Lymphoma

Archive of Oncology, 2012
Radiolabeled monoclonal antibodies for the treatment of follicular low-grade non-Hodgkin’s lymphoma have been available for several years in the United States and more recently throughout Europe. Since their introduction to treatment of refractory or relapsed patients, they have been evaluated for efficacy earlier in the course of the disease including
openaire   +3 more sources

CD38‐Targeted Theranostics of Lymphoma with 89Zr/177Lu‐Labeled Daratumumab

Advanced Science, 2021
Lymphoma is a heterogeneous disease with varying clinical manifestations and outcomes. Many subtypes of lymphoma, such as Burkitt′s lymphoma and diffuse large B cell lymphoma, are highly aggressive with dismal prognosis even after conventional ...
Lei Kang, Cuicui Li, Zachary T. Rosenkrans, Nan Huo, Zhao Chen, Emily B. Ehlerding, Yan Huo, Carolina A. Ferreira, Todd E. Barnhart, Jonathan W. Engle, Rongfu Wang, Dawei Jiang, Xiaojie Xu, Weibo Cai   +13 more
doaj   +1 more source

Quercetin‐zinc coordination polymer coated CaCO3 nanoparticles potentiate radiotherapy through reprogramming tumor immunosuppression

BMEMat, EarlyView.
Synthesis of QZCaCO3‐PEG to synergistically enhance the immunogenicity of radiotherapy through concurrent Zn2+‐induced cancer cell pyroptosis and Que‐mediated hypoxia amelioration through sequentially suppressing TGF‐β secretion and ECM deposition. Abstract Radiotherapy has demonstrated broad applications in treating solid tumors, but the hostile tumor
Chunjie Wang, Hengze Ding, Yu Hao, Honglin An, Ziliang Dong, Minming Chen, Yujie Zhu, Quguang Li, Bin Huang, Liangzhu Feng   +9 more
wiley   +1 more source

Radioimmunotherapy of human tumours [PDF]

Nature Reviews Cancer, 2015
The eradication of cancer remains a vexing problem despite recent advances in our understanding of the molecular basis of neoplasia. One therapeutic approach that has demonstrated potential involves the selective targeting of radionuclides to cancer-associated cell surface antigens using monoclonal antibodies.
Steven M, Larson, Jorge A, Carrasquillo, Nai-Kong V, Cheung, Oliver W, Press   +3 more
openaire   +2 more sources

RADIOIMMUNOTHERAPY IN THE TREATMENT OF MALIGNANCIES

Сибирский онкологический журнал, 2016
This review presents information about one of the promising areas of targeted therapy in modern oncology, which is called radioimmunotherapy. Particular attention is paid to the possibility of clinical application of this type of systemic treatment for ...
V. I. Chernov, O. D. Bragina, I. G. Sinilkin, A. A. Titskaya, R. V. Zelchan   +4 more
doaj   +1 more source

Recent Advances in Hepatocellular Carcinoma Treatment with Radionuclides

Pharmaceuticals, 2022
As the third leading cause of cancer death worldwide, hepatocellular carcinoma (HCC) is characterized by late detection, difficult diagnosis and treatment, rapid progression, and poor prognosis.
Ruiqi Liu, Hong Li, Yihua Qiu, Hongguang Liu, Zhen Cheng   +4 more
doaj   +1 more source

High Endothelial Venules in Small Cell Lung Cancer: Prognostic Subtypes and Therapeutic Implications for Immunoradiotherapy

International Journal of Cancer, EarlyView.
ABSTRACT Small cell lung cancer (SCLC) is a highly aggressive neuroendocrine malignancy with an immunosuppressive tumor microenvironment, and current immunotherapy provides limited benefit. This highlights the need to identify microenvironmental features enabling effective immune responses.
Jiatian Fang, Zilian Wang, Hui Wang, Jianxin Xue, Kai Kang   +4 more
wiley   +1 more source

Carbonic Anhydrase IX-Targeted α-Radionuclide Therapy with 225Ac Inhibits Tumor Growth in a Renal Cell Carcinoma Model

Pharmaceuticals, 2022
In this study, we compared the tumor-targeting properties, therapeutic efficacy, and tolerability of the humanized anti-CAIX antibody (hG250) labeled with either the α-emitter actinium-225 (225Ac) or the β--emitter lutetium-177 (177Lu) in mice.
Robin I. J. Merkx, Mark Rijpkema, Gerben M. Franssen, Annemarie Kip, Bart Smeets, Alfred Morgenstern, Frank Bruchertseifer, Eddie Yan, Michael P. Wheatcroft, Egbert Oosterwijk, Peter F. A. Mulders, Sandra Heskamp   +11 more
doaj   +1 more source